Two hundred and forty five questionnaires were returned from 587 patients, 149 of which yielded follow up data on patients receiving second line endocrine therapy following fulvestrant n 83 and tamoxifen n 66 cialis
Two hundred and forty five questionnaires were returned from 587 patients, 149 of which yielded follow up data on patients receiving second line endocrine therapy following fulvestrant n 83 and tamoxifen n 66 cialis
